CA3027612C - Molecules de liaison liant pd-l1 et lag -3 - Google Patents

Molecules de liaison liant pd-l1 et lag -3

Info

Publication number
CA3027612C
CA3027612C CA3027612A CA3027612A CA3027612C CA 3027612 C CA3027612 C CA 3027612C CA 3027612 A CA3027612 A CA 3027612A CA 3027612 A CA3027612 A CA 3027612A CA 3027612 C CA3027612 C CA 3027612C
Authority
CA
Canada
Prior art keywords
antibody molecule
seq
lag
cancer
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3027612A
Other languages
English (en)
Other versions
CA3027612A1 (fr
Inventor
Jamie Campbell
Nikole Sandy
Mihriban Tuna
Francisca Wollerton Van Horck
Katy Louise Everett
Miguel Gaspar
Matthew Kraman
Katarzyna Kmiecik
Mustapha Faroudi
Natalie Fosh
Barbara Hebeis
Original Assignee
F Star Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Star Therapeutics Ltd filed Critical F Star Therapeutics Ltd
Priority claimed from PCT/EP2017/065073 external-priority patent/WO2017220569A1/fr
Publication of CA3027612A1 publication Critical patent/CA3027612A1/fr
Application granted granted Critical
Publication of CA3027612C publication Critical patent/CA3027612C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne des molécules d'anticorps qui se lient au ligand 1 de la mort programmée (PD-L1) et au gène 3 d'activation des lymphocytes (LAG-3) Les molécules d'anticorps comprennent de préférence un site de liaison d'antigène à base de CDR pour PD-L1, et un site de liaison à L'antigène LAG-3 qui peut être situé dans boucles structurelles ou plus d'un domaine CH3 de la molécule d'anticorps. Les molécules d'anticorps de cette invention trouvent une application, au traitement du cancer, par exemple.
CA3027612A 2016-06-20 2017-06-20 Molecules de liaison liant pd-l1 et lag -3 Active CA3027612C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662352482P 2016-06-20 2016-06-20
US62/352,482 2016-06-20
PCT/EP2017/065073 WO2017220569A1 (fr) 2016-06-20 2017-06-20 Molécules de liaison liant pd-l1 et lag -3

Publications (2)

Publication Number Publication Date
CA3027612A1 CA3027612A1 (fr) 2017-12-28
CA3027612C true CA3027612C (fr) 2026-02-17

Family

ID=

Similar Documents

Publication Publication Date Title
JP7464644B2 (ja) Ｐｄ－ｌ１及びｌａｇ－３に結合する結合分子
US12187798B2 (en) LAG-3 binding members
CA3027612C (fr) Molecules de liaison liant pd-l1 et lag -3
HK40057934A (en) Binding molecules binding pd-l1 and lag-3
RU2784388C2 (ru) СВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕ PD-L1 и LAG-3
RU2784388C9 (ru) СВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕ PD-L1 и LAG-3
HK40001116B (en) Binding molecules binding pd-l1 and lag-3
HK40001116A (en) Binding molecules binding pd-l1 and lag-3
HK40001083A (en) Lag-3 binding members
HK40001083B (en) Lag-3 binding members